Skip to search formSkip to main contentSkip to account menu

SB-265805

Known as: SB 265805 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
The in vitro activity of gemifloxacin (SB-265805) was compared with that of other fluoroquinolones against 302 clinical isolates… 
2001
2001
Abstract The purpose of the study presented here was to determine the in vitro activity of gemifloxacin compared with that of 11… 
Highly Cited
2000
Highly Cited
2000
ABSTRACT Two hundred fifty isolates of Mycobacterium tuberculosis were evaluated for susceptibility to ciprofloxacin, ofloxacin… 
2000
2000
ABSTRACT In a rabbit model of Streptococcus pneumoniaemeningitis, 5 mg of gemifloxacin mesylate (SB-265805) per kg/h reduced the… 
2000
2000
This study investigated the in vitro potency of the novel quinolone agent gemifloxacin (SB-265805), in comparison with other… 
2000
2000
This study compared the in vitro bacteriostatic activity of gemifloxacin (SB-265805) and a panel of test antimicrobial agents… 
2000
2000
This study compared the bactericidal activity of gemifloxacin (SB-265805) and a panel of test quinolones against two… 
2000
2000
This study investigated the in vitro activity of gemifloxacin (SB-265805) against 50 recent clinical isolates of Streptococcus… 
1999
1999
SB-265805, formerly LB20304, is a novel naphthridone compound in the fluoroquinolone class of antimicrobial agents. This…